Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: Review of the literature and options for clinical practice

Drugs

Volumn 72, Issue 5, 2012, Pages 685-704

  Tragiannidis, Athanasios ^a,b   Dokos, Charalampos ^a,b   Lehrnbecher, Thomas ^c   Groll, Andreas H ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Amphotericin B; Anidulafungin; Cancer; Caspofungin; Children; Fluconazole; Haematopoietic stem cell therapy; Itraconazole; Leukaemia; Micafungin; Mycoses; Nystatin; Posaconazole; Transplantation; Triazoles; Voriconazole

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ASPERGILLOSIS; CANCER PROGNOSIS; CANDIDIASIS; CHEMOPROPHYLAXIS; CHILDHOOD CANCER; CONSOLIDATION CHEMOTHERAPY; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATALITY; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; INFECTION RATE; INFECTION RISK; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; SYSTEMIC MYCOSIS; TREATMENT OUTCOME;

ADOLESCENT; ANTIFUNGAL AGENTS; CHEMOPREVENTION; CHILD; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYCOSES; OPPORTUNISTIC INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 84858788453     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11599810-000000000-00000     Document Type: Review

References (130)

1. Benjamin Jr DK, Miller WC, Bayliff S, et al. Infections diagnosed in the first year after pediatric stem cell transplantation. Pediatr Infect Dis J 2002; 21: 227-34 (Pubitemid 34214140)
2. Zaoutis TE, Greves HM, Lautenbach E, et al. Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J 2004 Jul; 23 (7): 635-41 (Pubitemid 38924888)
3. Zaoutis T, Coffin S, Chu J, et al. Risk factors for mortality in children with candidemia. Pediatr Infect Dis J 2005; 24: 736-9 (Pubitemid 41140963)
4. Zaoutis TE, Heydon K, Chu JH, et al. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 2006; 117: 711-6
5. Rosen GP, Nielsen K, Glenn S, et al. Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr HematolOncol 2005; 27: 135-40 (Pubitemid 40397242)
6. Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 2008; 121: e1286-94
7. Dehority W, Willert J, Pong A. Zygomycetes infections in pediatric hematology oncology patients: a case series and review of the literature. J Pediatr Hematol Oncol 2009 Dec; 31 (12): 911-9
8. Hale KA, Shaw PJ, Dalla-Pozza L, et al. Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant. Br J Haematol 2010 Apr; 149 (2): 263-72
9. Mor M, Gilad G, Kornreich L, et al. Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer 2011; 56: 1092-7
10. Dornbusch HJ, Groll A, Walsh TJ. Diagnosis of invasive fungal infections in immunocompromised children. Clin Microbiol Infect 2010; 16: 1328-34
11. Berenguer J, Buck M, Witebsky F, et al. Lysiscentrifugation blood cultures in the detection of tissue-proven invasive candidiasis: disseminated versus single-organ infection. Diagn Microbiol Infect Dis 1993 Aug-Sep; 17 (2): 103-9 (Pubitemid 23294544)
12. Groll AH, Tragiannidis A. Recent advances in antifungal prevention and treatment. Semin Hematol 2009; 46: 212-29
13. Dvorak CC, Fisher BT, Sung L, et al. Antifungal prophylaxis in pediatric hematology/oncology: new choices and new data. Pediatr Blood Cancer. Epub 2011 Nov 18
14. Gramatges MM, Winter SS. Recommendations for broader coverage antifungal prophylaxis in childhood acutemyeloid leukemia: ASH evidence-based review 2011. Hematology Am Soc Hematol Educ Program 2011: 2011: 374-6
15. Hovi L, Saarinen-Pihkala UM, Vettenranta K, et al. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant 2000; 26: 999-1004
16. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-66 (Pubitemid 32173620)
17. Kobayashi R, Kaneda M, Sato T, et al. The clinical feature of invasive fungal infection in pediatric patients with hematologic and malignant diseases: a 10-year analysis at a single institution at Japan. J Pediatr Hematol Oncol 2008; 30: 886-90
18. Kaya Z, Gursel T, Kocak U, et al. Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis. Pediatr Blood Cancer 2009; 52: 470-5
19. Castagnola E, Rossi MR, Cesaro S, et al. Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia: results from a multi-center Italian study. Pediatr Blood Cancer 2010; 55: 1103-7
20. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-43 (Pubitemid 37100802)
21. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-703
22. Sipsas NV, Lewis RE, Tarrand J, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009; 115: 4745-52
23. Slavin MA, Sorrell TC, Marriott D, et al.; Australian Candidemia Study, Australasian Society for Infectious Diseases. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother 2010 May; 65 (5): 1042-51
24. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004 Aug 1; 39 (3): 309-17 (Pubitemid 39050477)
25. Geffers C, Gastmeier P. Nosocomial infections and multidrug-resistant organisms in Germany: epidemiological data from KISS (the Hospital Infection Surveillance System). Dtsch Arztebl Int 2011 Feb; 108 (6): 87-93
26. Tragiannidis A, Fegeler W, Rellensmann G, et al. Candidaemia in a European Paediatric University Hospital: a 10-year observational study. Clin Microbiol Infect 2012 Feb; 18 (2): e27-30
27. Mullen CA, Abd El-Baki H, Samir H, et al. Non-albicans Candida is the most common cause of candidemia in pediatric cancer patients. Support Care Cancer 2003; 11: 321-5 (Pubitemid 36723560)
28. Roilides E, Kadiltsoglou I, Zahides D, et al. Invasive candidosis in pediatric patients. Clin Microbiol Infect 1997 Apr; 3 (2): 192-7 (Pubitemid 27202309)
29. Wisplinghoff H, Seifert H, Tallent SM, et al. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J 2003 Aug; 22 (8): 686-91 (Pubitemid 36999643)
30. Pasqualotto AC, de Moraes AB, Zanini RR, et al. Analysis of independent risk factors for death among pediatric patients with candidemia and a central venous catheter in place. Infect Control Hosp Epidemiol 2007; 28: 799-804 (Pubitemid 47055918)
31. Blyth CC, Chen SC, Slavin MA, et al., Australian Candidemia Study. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 2009; 123: 1360-8
32. Zaoutis TE, Prasad PA, Localio AR, et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis 2010 Sep 1; 51 (5): e38-45
33. Dutta A, Palazzi DL. Candida non-albicans versus candida albicans fungemia in the non-neonatal pediatric population. Pediatr Infect Dis J 2011 Aug; 30 (8): 664-8
34. Steinbach WJ. Epidemiology of invasive fungal infections in neonates and children. Clin Microbiol Infect 2010 Sep; 16 (9): 1321-7
35. Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-66 (Pubitemid 35429674)
36. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33: 641-7 (Pubitemid 32762937)
37. Groll AH, Kurz M, Schneider W, et al. Five-year-survey of invasive aspergillosis in a paediatric cancer centre: epidemiology, management and long-term survival. Mycoses 1999; 42: 431-42 (Pubitemid 29470384)
38. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39: 425-9 (Pubitemid 46487308)
39. Pongas GN, Lewis RE, Samonis G, et al. Voriconazoleassociated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin Microbiol Infect 2009; 15 Suppl. 5: 93-7
40. Saegeman V, Maertens J, Meersseman W, et al. Increasing incidence of mucormycosis in University Hospital, Belgium. Emerg Infect Dis 2010; 16: 1456-8
41. Groll AH. Drug therapy in paediatric patients. Lancet 2001; 357 (9257): 719
42. European Community. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of medicinal products for paediatric use, amended by Regulation (EC) No 1902/2006 [online]. Available from URL: http://ec. europa.eu/health/documents/eudralex/vol-1/index-en.htm [Accessed 2011 Dec 1]
43. EuropeanMedicinesAgency (2001). ICHTopic E 11Clinical Investigation of Medicinal Products in the Paediatric Population. Note for guidance on clinical investigation of medicinal products in the paediatric population (CPMP/ICH/2711/99) [online]. Available from URL: http://www. emea.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/ WC500002926.pdf [Accessed 2011 Dec 1]
44. Food and Drug Administration. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients. Federal Register 1998; 63: 66632-72
45. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005; 49: 4536-45 (Pubitemid 41552583)
46. Zaoutis TE, Jafri HS, Huang LM, et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 2009; 123: 877-84
47. Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010; 29: 415-20
48. Li C, Sun P, Dong Y, et al. Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients. Antimicrob Agents Chemother 2011 May; 55 (5): 2098-105
49. Zaoutis T, Lehrnbecher T, Groll AH, et al. Safety experience with caspofungin in pediatric patients. Pediatr Infect Dis J 2009; 28: 1132-5
50. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005; 49: 3317-24 (Pubitemid 41060577)
51. Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008; 27: 820-6
52. van Burik JA, Ratanatharathorn V, Stepan DE, et al., National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-16
53. Hope WW, Seibel NL, Schwartz CL, et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 2007; 51: 3714-9 (Pubitemid 47519363)
54. Arrieta AC, Maddison P, Groll AH. Safety of micafungin in pediatric clinical trials. Pediatr Infect Dis J 2011 Jun; 30 (6): e97-102
55. Mora-Duarte J, Betts R, Rotstein C, et al., Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9 (Pubitemid 35461658)
56. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402
57. Kuse ER, Chetchotisakd P, da Cunha CA, et al., Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369 (9572): 1519-27 (Pubitemid 46670281)
58. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single-or multiple-dose administration. Antimicrob Agents Chemother 2004; 48: 2166-72 (Pubitemid 38691615)
59. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009; 53: 935-44
60. Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother 2010 Oct; 54 (10): 4116-23
61. Driscoll TA, Yu LC, Frangoul H, et al. Comparison of pharmacokinetics and safety of voriconazole intravenousto-oral switch in immunocompromised children and healthy adults. Antimicrob Agents Chemother 2011 Dec; 55 (12): 5770-9. Epub 2011 Oct 3
62. Driscoll TA, Frangoul H, Nemecek ER, et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults. Antimicrob Agents Chemother 2011 Dec; 55 (12): 5780-9
63. Groll AH, Tragiannidis A. Update on antifungal agents for paediatric patients. Clin Microbiol Infect 2010; 16: 1343-53
64. Bow EJ, Laverdiere M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherary recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002; 94: 3230-46 (Pubitemid 34670507)
65. Cornely OA, Ullmann AJ, Karthaous M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003; 101: 3365-72 (Pubitemid 36857916)
66. Glasmacher A, Prentice AG, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for haematological malignancies: evidence from a meta-analysis of 3597 patients. J Clin Oncol 2003; 21: 4616-26
67. Kim YJ, Sung KW, Hwang HS, et al. Efficacy of itraconazole prophylaxis for autologous stem cell transplantation in children with high-risk solid tumors: a prospective double-blind randomized study. Yonsei Med J 2011; 52: 293-300
68. Groll AH, Gea-Banacloche JC, Glasmacher A, et al. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003 Mar; 17 (1): 159-91 (Pubitemid 36514575)
69. Adler-Moore JP, Olson JA, Proffitt RT. Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis. J Antimicrob Chemother 2004; 54: 1096-102 (Pubitemid 40136748)
70. Ellis M. New dosing strategies for liposomal amphotericin B in high-risk patients. Clin Microbiol Infect 2008; 14 Suppl. 4: 55-64 (Pubitemid 351593917)
71. Penack O, Schwartz S, Martus P, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006; 17: 1306-12 (Pubitemid 44288223)
72. Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, doubleblind, placebo-controlled study. Bone Marrow Transplant 1999; 23: 163-8 (Pubitemid 29048218)
73. Mattiuzzi GN, Estey E, Raad I, et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 2003; 97 (2): 450-6 (Pubitemid 36133812)
74. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46: 1401-8 (Pubitemid 351589940)
75. Hong Y, Shaw PJ, Nath CE, et al. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother 2006; 50: 935-42 (Pubitemid 43327797)
76. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711-8 (Pubitemid 27386554)
77. Ringdén O, Andström EE, Remberger M, et al. Prophylaxis and therapy using liposomal amphotericin B (Am-Bisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation. Pediatr Transplant 1997; 1: 124-9 (Pubitemid 127684753)
78. Uhlenbrock S, Zimmermann M, Fegeler W, et al. Liposomal amphotericin B for prophylaxis of invasive fungal infections in high-risk paediatric patients with chemotherapy-related neutropenia: interim analysis of a prospective study. Mycoses 2001; 44: 455-63 (Pubitemid 34131792)
79. Bochennek K, Tramsen L, Schedler N, et al. Liposomal amphotericin B twice weekly as antifungal prophylaxis in pediatric hematologic malignancy patients. Clin Microbiol Infect 2011 Dec; 17 (12): 1868-74
80. Mehta P, Vinks A, Filipovich A, et al. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant 2006; 12: 235-40 (Pubitemid 43138018)
81. Kolve H, Ahlke E, Fegeler W, et al. Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation. J Antimicrob Chemother 2009; 64: 383-7
82. Lee JW, Seibel NL, Amantea M, et al. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr 1992; 120: 987-93
83. Brammer KW, Coates PE. Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin Microbiol Infect Dis 1994; 13: 325-9 (Pubitemid 24139810)
84. Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother 1999; 43: 1955-60 (Pubitemid 29395192)
85. de Repentigny L, Ratelle J, Leclerc JM, et al. Repeateddose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother 1998; 42: 404-8 (Pubitemid 28114453)
86. Groll AH, Wood L, Roden M, et al. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2002; 46: 2554-63 (Pubitemid 34793463)
87. Hennig S, Wainwright CE, Bell SC, et al. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clin Pharmacokinet 2006; 45: 1099-114 (Pubitemid 44631389)
88. Foot AB, Veys PA, Gibson BE. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant 1999; 24: 1089-93
89. Abdel-Rahman SM, Jacobs RF, Massarella J, et al. Singledose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. Antimicrob Agents Chemother 2007; 51: 2668-73 (Pubitemid 47206198)
90. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-51
91. Slavin M, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, doubleblind study. J Infect Dis 1995; 171: 1545-52
92. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-61
93. Menichetti F, Del Favero A, Martino P, et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. The GIMEMA Infection Program. Ann Intern Med 1994; 120: 913-8 (Pubitemid 24179153)
94. Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28: 331-40
95. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med 2003; 138: 705-13
96. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-33 (Pubitemid 38168674)
97. Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 1999; 28: 250-5
98. Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 2005; 131: 22-8 (Pubitemid 43899704)
99. Ninane J. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group. Eur J Clin Microbiol Infect Dis 1994; 13: 330-7 (Pubitemid 24139811)
100. Simon A, Besuden M, Vezmar S, et al. Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants. Support Care Cancer 2007; 15: 213-20 (Pubitemid 46332928)
101. Grigull L, Kuehlke O, Beilken A, et al. Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipients: a pilot study for evaluation of safety and efficacy. Pediatr Transplant 2007; 11: 261-6 (Pubitemid 46570141)
102. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-11 (Pubitemid 351269158)
103. Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 2011; 55: 4782-8
104. Lebeaux D, Lanternier F, Elie C, et al. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother 2009; 53: 5224-9
105. Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010; 88: 115-9
106. Krishna G, Sansone-Parsons A, Martinho M, et al. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007; 51: 812-8 (Pubitemid 46355260)
107. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240-8 (Pubitemid 34214142)
108. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59 (Pubitemid 46148777)
109. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47 (Pubitemid 46148776)
110. Wingard JR, Carter SL, Walsh TJ, et al., Blood and Marrow Transplant Clinical, Trials Network. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116: 5111-8
111. Marks DI, Pagliuca A, Kibbler CC, et al., IMPROVIT Study Group. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 2011; 155: 318-27
112. Mandhaniya S, Swaroop C, Thulkar S, et al. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study. Pediatr Hematol Oncol 2011; 33: e333-41
113. Molina JR, Serrano J, Sá nchez-García J, et al. Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCT. Bone Marrow Transplant. Epub 2011 May 16
114. Panagopoulou P, Fragandrea-Sidi F, Roilides E, et al. Antifungal prophylaxis with voriconazole in paediatric patients treated for hematological malignancies. Haematologica 2010; 95 Suppl. 2: 363
115. Chou LS, Lewis RE, Ippoliti C, et al. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy 2007; 27: 1644-50 (Pubitemid 350234313)
116. Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006; 50: 143-7 (Pubitemid 43042914)
117. Kusuki S, Hashii Y, Yoshida H, et al. Antifungal prophylaxis with micafungin in patients treated for childhood cancer. Pediatr Blood Cancer 2009; 53: 605-9
118. Mehta PA, Vinks AA, Filipovich A, et al. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant 2010; 16: 1458-62
119. Walsh TJ, Whitcomb PO, Revankar SG, et al. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995 Dec 1; 76 (11): 2357-62
120. Offner F, Cordonnier C, Ljungman P, et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998 May; 26 (5): 1098-103 (Pubitemid 28215472)
121. Martino R, Parody R, Fukuda T, et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 2928-36
122. Allinson K, Kolve H, Gumbinger HG, et al. Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cellrecipients. J Antimicrob Chemother 2008; 61: 734-42 (Pubitemid 351321154)
123. Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33: 943-8 (Pubitemid 38660128)
124. Cordonnier C, Rovira M, Maertens J, et al., Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants (VOSIFI) study group; Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010; 95: 1762-8
125. Krü ger WH, Rü ssmann B, de Wit M, et al. Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. Acta Haematol 2005; 113: 104-8
126. Vehreschild JJ, Sieniawski M, Reuter S, et al. Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry. Int J Antimicrob Agents 2009; 34: 446-50
127. de Fabritiis P, Spagnoli A, Di Bartolomeo P, et al. Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplant 2007; 40: 245-9 (Pubitemid 47108468)
128. Glasmacher A, Hahn C, Leutner C, et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999; 42 (7-8): 443-51 (Pubitemid 29470385)
129. Lehrnbecher T, Attarbaschi A, Duerken M, et al. Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis 2010 Aug; 29 (8): 1043-5
130. Richardson M, Lass-Flö rl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008 May; 14 Suppl. 4: 5-24 (Pubitemid 351593913)